XML 76 R57.htm IDEA: XBRL DOCUMENT
v3.21.1

Significant agreements (Details) $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jan. 31, 2020 item | Mar. 31, 2021 USD ($) | Mar. 31, 2020 USD ($)
Significant agreements |  |  |
Prepaid expenses and other current assets |  | $ 4,492 | $ 2,734
Regeneron Pharmaceuticals, Inc |  |  |
Significant agreements |  |  |
Payments received under the terms of the agreement |  | 5,100 | 3,000
Prepaid expenses and other current assets |  | $ 1,300 | $ 971
Bristol-Myers Squibb Company |  |  |
Significant agreements |  |  |
Number Of Patients | item | 125 |  |

X
- Definition It represents number of additional Cohort of patients with anti PDI failed melanoma. + References No definition available. + Details
Name: | repl_NumberOfPatients
Namespace Prefix: | repl_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of payments received under the terms of the agreement. + References No definition available. + Details
Name: | repl_ReceivedPaymentsUnderTermsOfAgreement
Namespace Prefix: | repl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=repl_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=repl_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |